Share Name Share Symbol Market Type Share ISIN Share Description
Silence Ther. LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +2.50p +2.29% 111.50p 108.00p 115.00p - - - 0.00 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -9.4 -10.4 - 59.25

Silence Therapeutics (SLN) Latest News

More Silence Therapeutics News
Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Share Charts

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date Time Title Posts
30/11/201613:53Silence Therapeutics (the old SR Pharma)47,154.00
06/10/201608:04Gower Productions Presents ....."PREDICTA BID"52.00
29/5/201309:32Silence Therapeutics - news and views1,412.00
15/2/201308:57SLN - I see no ships, but I do see 10p looming, ahoy!368.00

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

Silence Therapeutics Daily Update: Silence Ther. is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 109p.
Silence Ther. has a 4 week average price of 113.14p and a 12 week average price of 116.67p.
The 1 year high share price is 170p while the 1 year low share price is currently 0p.
There are currently 53,134,957 shares in issue and the average daily traded volume is 4,274 shares. The market capitalisation of Silence Ther. is £59,245,477.06.
callumross: Milestone payments announced yesterday are for Quark entering Phase 3 and are IN ADDITION to the 15% which is still only a possibility depending on the outcome of phase 3 trials (the primary endpoint in the quark Phase 2 trial of 30% was achieved in a very specific subset of patients amounting to 50% of the trial participants). Surprised we didn't see a strong bounce in the share price on the announcement yesterday.
pwilk47490: Share Price slump gaining momentum! :-(
benson384: Waterloo........SLN won courtcase in Europe re-patent challenged by Alnylam (?). They thought ir worth challenging along with 3 other co's and lost. The amount of money they have and their market Cap circa $8-10bn why not just buy SLN.....? For years I have heard that SLN's tecnology/delivery is way ahead of Yanks so why not just now buy it........? Victor Kiam style !!!! Waterloo, I think you ben about a long time so your memory may pick up points I am raising and agree.........who cares all we want is a share price that now reflects the progress that has been made and the future £5 now looks cool £10 in £18 months mayeven look cheap......who knows.? No knowledge other than published and kept eye on this outfit for many years, I amy be wrong but patience is tittering on cliff of rich/reward versus sh.t...... Very open to critiscm by all, re my thoughts.
stuart14: I'm staying in. This announcement is fishy. Telling the market you are considering raising funds is a sure-fire 100% guaranteed way to generate stock selling and a lower share-price. Why do they need the shares though?
laylap: He will no doubt pause as this climbs - inevitably picking up cheaper shares as the share price falls (much as you say). So the question is why isn't he doing this in a more structured approach - i.e. taking time.....waiting the fall in share price? What's the hurry with snapping up significant numbers of shares in such a short time...........?
geoffmanana: SLN obviously has the potential to be a FTSE 250 company,but what will the share price be? I used to be a shareholder in Kenmare Resourses (KMR) a number of years ago. I bought in at 30p and they had a Market Cap of peanuts. Today they are 26p with a MC of £ other words they have diluted themselves to Hell for the benefit of the Institutions and the detriment of the Private Investor. Will SLN go the same way?........probably. Our main hope is the substantial payments SLN will receive along the way if successful. I'm holding........but watch,wait & don't be afraid to sell is my advice fwiw.
the_doctor: 'No faith in the bod here' It isnt the bod's fault There has been little they can do The issue has been that a) SLN was ramped up by IR's lot + posters on here, but failed to deliver deals b) RNAi in general has moved out of favour pending further data = SLN share price was hammered down and funds have been raised at worsening levels It is now really a case of - seeing what tech deals they can get (they've just done a small one) - keeping existing deals going (AZ renewed and Dainippon progressing) - hoping that external clinical products continue and give milestones (out of their hands) - moving Atu027 forwards and driving a deal there (scheduled for 2012) - leveraging Atu027 to push for more tech deals (as above) - keeping other tech platforms moving forward They've been doing all that. Not really a whole lot more the bod can do.
steve strang: sorry, my mistake, it means 'buoyant' wish the SLN share price was manana... ;-)
stony tiger: you or the SLN share price? ;-)
masurenguy: This is still a speculative research company which has clocked up £24m in losses over the past 4 years on comparatively token sales of £10m during that timeframe. The SLN share price is driven by sentiment and interpretation of likely progress in ongoing clinical trials. At the moment the former is dire and the latter is uncertain. The current market climate is also very unfavourable to 'jam tomorrow' companies rather than solid performers with a track record and a dividend yield. Consequently this is a very speculative share to own and any investment should be of the order that it could be written off without any real pain. The plus point here at the moment is that they would appear to have enough cash to cover the next 12 months. Some breakthrough will be necessary during this period since any further placing - if achievable - would be at such a low price that it would dilute existing shareholders to almost nothing. The other risk for shareholders here would be if the main investors decided to delist and take it private at a very low price. Not saying that this will happen just considering the various possibilities !
Silence Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20161203 23:51:17